Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A replay of the webcast will be available for at least 30 days on the company's investor relations website.
Krystal Biotech (NASDAQ: KRYS), un'azienda biotecnologica in fase commerciale, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per luned矛 4 agosto 2025, prima dell'apertura dei mercati statunitensi.
La societ脿 terr脿 una conference call e una diretta web alle 8:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sul business. La registrazione della diretta sar脿 disponibile per almeno 30 giorni sul sito web delle relazioni con gli investitori dell'azienda.
Krystal Biotech (NASDAQ: KRYS), una empresa biotecnol贸gica en etapa comercial, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el lunes 4 de agosto de 2025, antes de la apertura de los mercados en EE. UU.
La compa帽铆a realizar谩 una llamada conferencia y una transmisi贸n en vivo a las 8:30 am ET del mismo d铆a para discutir los resultados y ofrecer una actualizaci贸n del negocio. La repetici贸n de la transmisi贸n estar谩 disponible durante al menos 30 d铆as en el sitio web de relaciones con inversionistas de la empresa.
Krystal Biotech (NASDAQ: KRYS)電� 靸侅梾 雼硠鞐� 鞛堧姅 靸濍獏瓿淀暀 須岇偓搿滌劀, 2025雲� 8鞗� 4鞚� 鞗旍殧鞚� 氙戈淡 鞁滌灔 臧滌灔 鞝� 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
須岇偓電� 臧欖潃 雮� 霃欕秬 響滌鞁� 鞓れ爠 8鞁� 30攵�鞐� 鞁れ爜 氚滍憸 氚� 靷梾 鞐呺嵃鞚错姼毳� 鞙勴暅 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼 雲鬼檾電� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 斓滌唽 30鞚� 霃欖晥 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Krystal Biotech (NASDAQ : KRYS), une entreprise biotechnologique en phase commerciale, a programm茅 l'annonce de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le lundi 4 ao没t 2025, avant l'ouverture des march茅s am茅ricains.
La soci茅t茅 organisera une conf茅rence t茅l茅phonique et une diffusion en direct 脿 8h30 ET le m锚me jour pour discuter des r茅sultats et fournir une mise 脿 jour commerciale. La rediffusion de la diffusion sera disponible pendant au moins 30 jours sur le site web des relations investisseurs de l'entreprise.
Krystal Biotech (NASDAQ: KRYS), ein Biotechnologieunternehmen in der kommerziellen Phase, hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r Montag, den 4. August 2025 geplant, und zwar vor 脰ffnung der US-M盲rkte.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Gesch盲ftsupdate zu geben. Eine Aufzeichnung des Webcasts wird mindestens 30 Tage lang auf der Investor-Relations-Website des Unternehmens verf眉gbar sein.
- None.
- None.
PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- (the 鈥淐ompany鈥�) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on聽Monday, August 4, 2025, prior to the open of U.S. markets.
The Company鈥檚 management will also host a conference call and webcast at聽8:30 am ET on聽Monday, August 4, 2025, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: .
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company鈥檚 website at聽.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK庐, the Company鈥檚 first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).
CONTACT
Investors and Media:
St茅phane Paquette, PhD
Krystal Biotech
[email protected]
FAQ
When will Krystal Biotech (KRYS) report Q2 2025 earnings?
What time is Krystal Biotech's Q2 2025 earnings call?
How can I access Krystal Biotech's Q2 2025 earnings webcast?
Where can I find the replay of Krystal Biotech's Q2 2025 earnings call?
